Inbios - development of point-of-care andlaboratory-based immunoassays for presumptive diagnosis of zika virus infection

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201600014C
Awardee
Awarding agency
Obligated
$7,735,011

Award facts

Contract value 100% obligated
$7,735,010.61 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Seattle, WA 98104, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00014 $0
Funding Only Action P00013 · Development of point-of-care and laboratory-based immunoassays for presumptive diagnosis of zika virus infection -$1,732,871
Other Administrative Action P00012 $0
Other Administrative Action P00011 · No-cost admin MOD to change contracting officers. IPP clause notice. No other changes apply. $0
Other Administrative Action P00010 · No-cost admin MOD to clarify MOD 8 & 9 contract end date remains 09/30/2023. No other changes apply. $0
Supplemental Agreement for work within scope P00009 · No cost, clin 0001 and clin 0002 POP extension from 6/30/2021 to 12/31/2021 to accommodate optimization of the GOV't's investment in up-scaling contractor's… $0
Supplemental Agreement for work within scope P00008 · No cost POP extension for clin 1 & clin 2 from 12/31/2021 to 09/30/2023 to complete clinical studies delayed by covid-19 emergency demands. $0
Supplemental Agreement for work within scope P00007 · No cost, clin 0001 POP extension from 6/30/2021 to 12/31/2021 to accommodate optimization of the GOV't's investment in up-scaling contractor's manufacturing and… $0
Supplemental Agreement for work within scope P00006 · No cost, clin 0001 extension of period of performance to 6/30/2021 due to unforeseen conditions and pandemic caused INT'l border closing impeding critical… $0
Other Administrative Action P00005 · No cost extension of period of performance from 12/6/2019 to 9/30/2020 $0
Other Administrative Action P00004 $0
Supplemental Agreement for work within scope 3 $0
Other Administrative Action 2 $4,354,808
Other Administrative Action 1 $0
Original award $5,113,074
Show all 15

About this award

Written by GovTribe AI ·

The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a cost-plus-fixed-fee definitive contract worth $7,735,010.61 to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the development of point-of-care and laboratory-based immunoassays for the presumptive diagnosis of Zika virus infection. This contract is not set aside. Inbios is a key partner to federal agencies, particularly during the COVID-19 pandemic, having secured numerous contracts to procure over-the-counter COVID-19 tests, develop diagnostic devices, and supply various test kits. Inbios has also received federal grants from the National Institute of Allergy and Infectious Diseases to advance diagnostic capabilities for neglected tropical diseases and emerging infectious diseases.

Quick answers

Who was awarded contract HHSO100201600014C?

HHSO100201600014C was awarded to Inbios International Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 27, 2016.

How much is contract HHSO100201600014C worth?

The government has obligated $7,735,011 on HHSO100201600014C.

Was contract HHSO100201600014C competed?

The extent of competition for HHSO100201600014C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login